Releases Details

Exercise of options and PDMR dealing

Oct 3, 2024
PDF Version
RNS Number : 8297G
MaxCyte, Inc.
03 October 2024
 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Exercise of options and PDMR dealing

 

ROCKVILLE, MD, October 3, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 1 October 2024 and 2 October 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive Director of the Company, exercised options over 47,689 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between $3.625 and $3.880 per Common Stock ("Sale"). The sold shares represent approximately 7.94% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.

 

Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 324,190 options over Common Stock and 21,367 restricted stock units.

 

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

ir@maxcyte.com

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Stanley Erck

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte, Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Exercise of Options over common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$0.040

26,082







d)

 

Aggregated information




- Aggregated volume

26,082



- Price

$0.040



e)

 

Date of the transaction

 

 

1 October 2024

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Stanley Erck

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte, Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Sale of common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$3.6900

200




$3.6950

1301




$3.7000

200




$3.7050

1600




$3.7100

100




$3.7150

900




$3.7200

466




$3.7300

1001




$3.7350

1666




$3.7400

200




$3.7450

800




$3.7500

349




$3.7550

975




$3.7650

2700




$3.7700

700




$3.7750

1700




$3.7800

104




$3.7850

1000




$3.7950

1200




$3.8000

200




$3.8050

200




$3.8150

1600




$3.8200

200




$3.8250

700




$3.8300

607




$3.8350

300




$3.8400

200




$3.8450

1500




$3.8500

300




$3.8600

600




$3.8650

713




$3.8700

1000




$3.8750

100




$3.8800

500







d)

 

Aggregated information




- Aggregated volume

26,082



- Price

$3.7784



e)

 

Date of the transaction

 

 

1 October 2024

f)

 

 

 

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Stanley Erck

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte, Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Exercise of Options over common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$0.040

21,607







d)

 

Aggregated information




- Aggregated volume

21,607



- Price

$0.040



e)

 

Date of the transaction

 

 

2 October 2024

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Stanley Erck

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte, Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Sale of common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$3.6250

400




$3.6300

200




$3.6350

109




$3.6400

300




$3.6450

50




$3.6500

13




$3.6550

50




$3.6600

200




$3.6650

200




$3.6700

400




$3.6750

305




$3.6800

1078




$3.6850

525




$3.6900

1700




$3.7000

1037




$3.7100

240




$3.7150

1040




$3.7200

9400




$3.7210

900




$3.7250

251




$3.7400

467




$3.7500

142




$3.7650

100




$3.7700

2500







d)

 

Aggregated information




- Aggregated volume

21,607



- Price

$3.7131



e)

 

Date of the transaction

 

 

2 October 2024

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAPEDELELFEA